.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,184,201

« Back to Dashboard

Details for Patent: 6,184,201

Title: Intestinotrophic glucagon-like peptide-2 analogs
Abstract:Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
Inventor(s): Drucker; Daniel J. (Toronto, CA), Crivici; Anna E. (San Diego, CA), Sumner-Smith; Martin (Bolton, CA)
Assignee: NPS Allelix Corp. (Mississauga, CA)
Filing Date:Apr 08, 1997
Application Number:08/835,538
Claims:1. A GLP-2 analog, or a pharmaceutically acceptable salt thereof, which has intestinotrophic activity and which has the formula (SEQ ID NO: 1):

R1-(Y1)m-X1-X2-X3-X4-Ser5-Phe6-Ser7-Asp8-(P1)-Leu14-Asp15-Asn16-Leu17-Ala18 -X19-X20-Asp21-Phe22-(P2)-Trp25-Leu26-Ile27-Gln28-Thr29-Lys30-(P3)-(Y2)n-R2 ,

wherein:

TBL X1 is His or Tyr X2 is Ala or an Ala-replacement amino acid which confers on the analog or salt resistance to cleavage by human DPP-IV enzyme; X3 is Pro or HPro; X4 is Gly or Ala; P1 is Glu-X10-Asn-Thr-Ile (SEQ ID NO. 3) or Tyr-Ser- Lys-Tyr (SEQ ID NO. 4); X10 is Met or an oxidatively stable Met-replacement amino acid; X19 is Ala or Thr; X20 is Arg, Lys, His or Ala; P2 is Ile-Asn, Ile-Ala or Val-Gln; P3 is a covalent bond, or is Ile, Ile-Thr or Ile-Thr-Asp; R1 is H or an N-terminal blocking group; R2 is OH or a C-terminal blocking group; Y1 is one or two amino acids selected from the group consisting of Arg, Lys and His; Y2 is one or two amino acids selected from the group consisting of Arg, Lys and His; m and n, independently, are 0 or 1

2. The GLP-2 analog or salt according to claim 1, wherein the analog or salt has at least one amino acid substitution selected from the group consisting of:

a) X2 is an amino acid which confers on the analog or salt resistance to cleavage by human DPP-IV enzyme;

b) X10 is an oxidatively stable Met-replacement amino acid; and

c) X20 is His or Lys.

3. The GLP-2 analog or salt according to claim 2, wherein X2 is an amino acid which confers on the analog or salt resistance to cleavage by human DPP-IV enzyme.

4. The GLP-2 analog or salt according to claim 3, wherein X2 is D-hPr, D-Pro, D-Ala, Gly, Val, Glu, Lys, Arg, Leu or Ile.

5. The GLP-2 analog or salt according to claim 3, which has at least one of the following:

a) X1 is Tyr;

b) X4 is Ala;

c) X10 is an oxidatively stable Met-replacement amino acid:

d) X20 is Ala;

e) P2 is Ile-Ala or Val-Gln.

6. The GLP-2 analog or salt according to claim 2, wherein X10 is Val, Ile, Asn, Glu, Gln, Tyr, Phe, Leu, Nle, Ala, Ser or Gly.

7. A pharmaceutical compositions comprising a GLP-2 analog, or pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically acceptable carrier.

8. A method for promoting the growth of small bowel tissue in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 7 to promote the growth of small bowel tissue.

9. A method for treating a gastrointestinal disease, comprising administering to a patient having the gastrointestinal disease an effective amount of a GLP-2 analog, or a pharmaceutically acceptable salt thereof, according to claim 1 to promote the growth of small bowel tissue and a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the gastrointestinal disease.

10. The method according to claim 9, wherein the gastrointestinal disease is selected from the group consisting of ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or chemotherapeutic agents, and short bowel syndrome.

11. An intestinotrophic analog of a human GLP-2, or a pharmaceutically acceptable salt thereof, wherein the analog or salt has in place of Asp.sup.3 either Pro or HPro, and at least one of the following:

a) in place of Ala.sup.2 is an amino acid which confers on the analog or salt resistance to cleavage by human DPP-IV enzyme;

b) in place of Met.sup.10 is an amino acid which is oxidatively stable; and

c) in place of Arg.sup.20 is an amino acid other than Arg.

12. The GLP-2 analog or salt according to claim 11, which has an amino acid substitution in place of Ala.sup.2, and wherein the substitution is D-hPr, D-Pro, D-Ala, Gly, Val, Glu, Lys, Arg, Leu or Ile.

13. The GLP-2 analog or salt according to claim 11, which has an amino acid substitution in place of Met.sup.10, wherein the substitution is Val, Ile, Asn, Glu, Gln, Tyr, Phe, Leu, Nle, Ala, Ser or Gly.

14. A pharmaceutical composition, comprising a GLP-2 analog, or a pharmaceutically acceptable salt thereof, according to claim 11, and a pharmaceutically acceptable carrier.

15. A method for promoting the growth of small bowel tissue in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 14, to promote the growth of small bowel tissue.

16. A method for treating a gastrointestinal disease, comprising administering to a patient having the gastrointestinal disease an effective amount of a GLP-2 analog, or a pharmaceutically acceptable salt thereof, according to claim 11, to promote the growth of small bowel tissue and pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the gastrointestinal disease.

17. The method according to claim 16, wherein the gastrointestinal disease is selected from the group consisting of ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or chemotherapeutic agents, and short bowel syndrome.

18. A method of identifying intestinotrophic analogs of GLP-2, comprising the steps of:

a) obtaining a GLP-2 analog according to claim 1;

b) administering to a mammal said analog using a regimen capable of eliciting an intestinotrophic effect when utilized for rat GLP-2; and

c) determining the effect of said analog on small bowel weight relative to a mock treated control mammal, whereby said intestinotrophic analog of GLP-2 is identified as an analog which elicits an increase in said weight.

19. An intestinotrophic GLP-2 analog selected from the group consisting of:

[Ser.sup.2, Gln.sup.3 ]humanGLP-2 (1-33);

[Gly.sup.2, Ala.sup.25 ]humanGLP-2(1-33);

[Gly.sup.2, Ala.sup.26 ]humanGLP-2(1-33);

[Gly.sup.2, Ala.sup.14 ]humanGLP-2(1-33);

[Gly.sup.2, Ala.sup.23 ]humanGLP-2(1-33);

[Gly.sup.2, Ala.sup.30 ]humanGLP-2(1-33);

[Tyr.sup.1, Gly.sup.2 ]humanGLP-2(1-33);

[Gly.sup.2, Arg.sup.34 ]humanGLP-2(1-34);

[Gly.sup.2, Tyr.sup.34 ]humanGLP-2 (1-34);

[tBuGly.sup.2 ] humanGLP-2;

[Asp.sup.2 ]humanGLP-2 (1-33);

[Glu.sup.2 ]humanGLP-2 (1-33);

[Phe.sup.2 ]humanGLP-2 (1-33);

[His.sup.2 ]humanGLP-2(1-33);

[Ile.sup.2 ]humanGLP-2(1-33);

[Lys.sup.2 ]humanGLP-2(1-33);

[Met.sup.2 ]humanGLP-2(1-33);

[Asn.sup.2 ]humanGLP-2 (1-33);

[Pro.sup.2 ]humanGLP-2(1-33);

[Gln.sup.2 ]humanGLP-2(1-33);

[Ser.sup.2 ]humanGLP-2(1-33);

[Thr.sup.2 ]humanGLP-2(1-33);

[Val.sup.2 ]humanGLP-2(1-33);

[Tyr.sup.2 ]humanGLP-2(1-33);

[D-Ala.sup.2 ]humanGLP-2(1-33);

[Pen.sup.2 ]humanGLP-2 (1-33);

[bAla.sup.2 ]humanGLP-2 (1-33);

[aAbu.sup.2 ]humanGLP-2(1-33);

[Nval.sup.2 ]humanGLP-2(1-33);

[PhGly.sup.2 ]humanGLP-2(1-33); and

[Aib.sup.2 ]humanGLP-2(1-33).

20. An intestinotrophic GLP-2 analog selected from the group consisting of:

[Asn.sup.33 ]humanGLP-2(1-33);

[Nle.sup.10 ]ratGLP-2(1-33); and

[Met(O).sup.10 ]ratGLP-2 (1-33).

21. An intestinotrophic GLP-2 analog selected from the group consisting of:

Ac-ratGLP-2(1-33);

ratGLP-2(1-30);

ratGLP-2(1-25);

ratGLP-2(1-33)amide;

[Arg-.sup.2 Arg-.sup.1 ]ratGLP-2 (2-33);

[Pro.sup.1 ]humanGLP-2 (1-33);

[Gln.sup.20 ]humanGLP-2(1-33);

[Asp.sup.1 ]humanGLP-2 (1-33);

[Tyr.sup.34 ]humanGLP-2 (1-34);

[desNH2Tyr.sup.1 ]humanGLP-2 (1-33);

[Thr.sup.5 ]humanGLP-2 (1-33);

[Ser.sup.16 Arg.sup.17, Arg.sup.18 ]humanGLP-2(1-33);

[Agm.sup.34 ]humanGLP-2(1-34);

[Arg.sup.30 ]humanGLP-2(1-33);

[Ala.sup.5, Ala.sup.7 ]humanGLP-2(1-33);

[Glu.sup.33 ]humanGLP-2(1-33);

[Phe.sup.25 ]humanGLP-2(1-33); and

[Tyr.sup.25 ]humanGLP-2(1-33).

22. A pharmaceutical composition comprising a therapeutically effective amount of a GLP-2 analog according to claim 21, and a pharmaceutically acceptable carrier.

23. A method for promoting growth of small bowel tissue in a patient in need thereof, comprising the step of administering to the patient the pharmaceutical composition of claim 22.

24. A method for treating a gastrointestinal disease, comprising administering to a patient having the gastrointestinal disease an effective amount of a GLP-2 analog, or a pharmaceutically acceptable salt thereof, according to claim 21, to promote the growth of small bowel tissue and a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the gastrointestinal disease.

25. The method according to claim 24, wherein the gastrointestinal disease is selected from the group consisting of ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or chemotherapeutic agents, and short bowel syndrome.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc